GlaxoSmithKline Newsroom

GSK Plc (GSK) Q1 2025 Earnings Conference Call Transcript Summary

moomoo AI12:37 ET · Conference Call

European Equities Traded in the US as American Depositary Receipts Drop Sharply in Wednesday Trading

MT NewswiresApr 30 11:14 ET

GlaxoSmithKline (GSK) Gets a Hold From UBS

TipRanksApr 30 09:57 ET · Ratings

Sector Update: Health Care Stocks Decline Pre-Bell Wednesday

MT NewswiresApr 30 09:14 ET

Sector Update: Health Care

MT NewswiresApr 30 08:55 ET

US Economy Shrinks in Q1, Driving Premarket Losses for US Equity Futures

MT NewswiresApr 30 08:53 ET

6-K: Report of foreign private issuer (related to financial reporting)

SECApr 30 08:12 ET · Announcements

Express News | GSK Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Adjusted EPS Guidance. Also, the Company Raised Its FY25 Sales Guidance Above Estimates

BenzingaApr 30 07:45 ET

Jefferies Remains a Hold on GlaxoSmithKline (GSK)

TipRanksApr 30 07:18 ET · Ratings

GSK Posts Q1 Beat Thanks to Specialty Medicines

Seeking AlphaApr 30 07:00 ET

GSK Q1 Core Earnings, Revenue Increase

MT NewswiresApr 30 05:20 ET

GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk

WSJApr 30 04:54 ET

GSK Affirms Its FY25 Guidance And Expects Its Turnover To Increase Between 3%-5% And Core Operating Profit To Increase Between 6%-8%. Core EPS Is Expected To Increase Between 6%-8%

BenzingaApr 30 04:51 ET

Earnings Preview: GSK to Report Financial Results on April 30

Moomoo NewsApr 30 04:45 ET

GSK Q1 Adj. EPS $1.13 Beats $1.04 Estimate, Sales $9.46B Beat $7.46B Estimate

BenzingaApr 30 04:34 ET

Research Alert: Q1 2025 Results Beat Estimates As Specialty Medicines Offset Weaker Vaccines

MT NewswiresApr 30 04:15 ET · Ratings

GSK's Specialty Meds Sustain Growth, Blenrep Comeback Remains Key -- Market Talk

WSJApr 30 03:49 ET

Asthma and HIV drugs drive performance growth. GlaxoSmithKline (GSK.US) Q1 profits exceeded expectations, maintaining the annual performance outlook.

The company's profits in the first quarter exceeded expectations, particularly strong sales of asthma and HIV treatment drugs offset the negative impact of the overall vaccine Business line sales performance being below expectations.

Zhitong FinanceApr 30 02:55 ET

GSK Sales, Profit Rise on Boost From Cancer Drugs

WSJApr 30 02:22 ET

GSK: Confident in Long-Term Outlook

Dow JonesApr 30 02:03 ET